News

As part of the agreement, Vical will develop and provide a DNA vaccine encoding the glycoprotein antigen of the 2014 Zaire strain of Ebola virus to AnGes, which

The collaboration comes with the possibility of a one-year extension and will be focused on the development of new mRNA-based treatments and vaccines against four undisclosed viruses. As

The data will be presented during a poster session at the 2015 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium taking place in San Francisco from January

The study assessed BRILINTA (ticagrelor) tablets at either 60mg twice daily or 90mg twice daily plus low-dose aspirin for the secondary prevention of atherothrombotic events in patients who

The aim of the new collaboration is the research and development of small molecule inhibitors of oncogenic Ras for the treatment of cancer. Ras is the most frequently

The trial enrolled 73 children with mild to moderate atopic dermatitis into a four-week double-blind period, followed by a four-week open label extension for those patients who wish

Hanmi Pharmaceutical also will be making a strategic investment in Allegro that will advance and accelerate the global development program for Luminate. Under the terms of the agreements,

Actavis will immediately begin marketing approximately 20 injectable products across a number of therapeutic categories in the US. The Company will be a leader in Oncology, with nearly

"This new patent allowance is representative of our intellectual property strategy aimed at protecting and enhancing the value of VAL-083," stated Jeffrey Bacha, DelMar’s president and CEO. "This